N-[2-(dimethylamino)ethyl]-N-methyl-N-(5-nitro-2-pyridinyl)amine | 882873-18-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: N-[2-(dimethylamino)ethyl]-N-methyl-N-(5-nitro-2-pyridinyl)amine
• 英文别名: N,N,N'-trimethyl-N'-(5-nitro-pyridin-2-yl)-ethane-1,2-diamine；N,N,N'-trimethyl-N'-(5-nitropyridin-2-yl)ethane-1,2-diamine
• CAS: 882873-18-9
• 化学式: C₁₀H₁₆N₄O₂
• 分子量: 224.263
• InChiKey: RUPMFNVTBQXDTQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[2-(dimethylamino)ethyl]-N-methyl-N-(5-nitro-2-pyridinyl)amine 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以42%的产率得到N2-(2-(dimethylamino)ethyl)-N2-methylpyridine-2,5-diamine
  参考文献：
  名称：

  [EN] PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES
  [FR] DÉRIVÉS DE PYRIMIDINE CAPABLES D'INHIBER UNE OU PLUSIEURS KINASES

  摘要：

  本发明的第一个方面涉及式(I)的化合物，或其药学上可接受的盐或酯，式(I)如下：其中：R1为C3-8环烷基；X为O、NR7或C3-6杂环烷基；R2为芳基、杂芳基、融合或未融合的芳基-C3-6杂环烷基或融合或未融合的杂芳基-C3-6杂环烷基，每个基可选择地由来自芳基、杂芳基、C1-6烷基、C3-7环烷基和A基的一个或多个取代基取代，其中所述C1-6烷基基可选择地由来自芳基、杂芳基、R10和A基的一个或多个取代基取代，所述杂芳基可选择地由一个或多个R10基取代；以及所述C3-6杂环烷基基可选择地包含一个或多个来自氧、硫、氮和CO的基；R3为C1-6烷基，可选择地由一个或多个来自芳基、杂芳基、-NR4R5、-OR6、-NR7(CO)R6、-NR7(CO)NR4R5、-NR7SO2R6、-NR7COOR7、-CONR4R5、C3-6杂环烷基和式(a, b, c)的取代基取代；其中R4-7和A如权利要求中所定义。进一步方面涉及所述化合物在治疗各种治疗性疾病中的使用，特别是作为一个或多个激酶的抑制剂。

  公开号：

  WO2009122180A1
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 、 N,N,N'-三甲基乙二胺 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 N-[2-(dimethylamino)ethyl]-N-methyl-N-(5-nitro-2-pyridinyl)amine
  参考文献：
  名称：

  EP1798221

  摘要：

  公开号：

文献信息

• Compound
  申请人：Mciver Edward Giles

  公开号：US20100056524A1

  公开（公告）日：2010-03-04

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R 1 is C 3-8 -cycloalkyl; X is O, NR 7 or C 3-6 -heterocycloalkyl; R 2 is aryl, heteroaryl, fused or unfused aryl-C 3-6 -heterocycloalkyl or fused or unfused heteroaryl-C 3-6 -heterocycloalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C 1-6 -alkyl, C 3-7 -cycloalkyl and a group A, wherein said C 1-6 -alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R 10 and a group A, said heteroaryl group is optionally substituted by one or more R 10 groups; and wherein said C 3-6 -heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R 3 is C 1-6 -alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, —NR 4 R 5 , —OR 6 , —NR 7 (CO)R 6 , —NR 7 (CO)NR 4 R 5 , —NR 7 SO 2 R 6 , —NR 7 COOR 7 , —CONR 4 R 5 , C 3-6 -heterocycloalkyl and wherein R 4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.

  本发明的第一方面涉及化合物(I)的公式，或其药学上可接受的盐或酯，其中： R1是C3-8环烷基；X是O，NR7或C3-6杂环烷基；R2是芳基、杂芳基、融合或未融合的芳基-C3-6杂环烷基或融合或未融合的杂芳基-C3-6杂环烷基，其中每个基团可选地由一个或多个取代基选自芳基、杂芳基、C1-6烷基、C3-7环烷基和A组成，其中所述的C1-6烷基可选地由一个或多个取代基选自芳基、杂芳基、R10和A组成，所述的杂芳基可选地由一个或多个R10基团取代；其中所述的C3-6杂环烷基可选地包含一个或多个选自氧、硫、氮和CO的基团；R3是C1-6烷基，可选地被一个或多个取代基选自芳基、杂芳基、-NR4R5、-OR6、-NR7(CO)R6、-NR7(CO)NR4R5、-NR7SO2R6、-NR7COOR7、-CONR4R5、C3-6杂环烷基和其中R4-7和A如权利要求所定义。 进一步的方面涉及所述化合物在治疗各种治疗性疾病中的应用，特别是作为一个或多个激酶的抑制剂。
• 2-Arylcarboxamide-Nitrogenous Heterocycle Compound
  申请人：Suzuki Takao

  公开号：US20070299070A1

  公开（公告）日：2007-12-27

  A compound represented by the formula [I]: [wherein R 1 and R 2 are the same or different and each represents C 1-6 alkyl, C 3-8 cycloalkyl, et al; R 3a , R 3b , and R 4 are the same or different and each represents hydrogen, C 1-6 alkyl, et al; X represents —N—, —CH—, et al; Y, represents a single bond, C 1-3 alkylene, et al; Y 2 represents C 1-4 alkylene, oxy(C 1-4 alkylene), et al; Ar 1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar 2 represents a 5 - or 6 -membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.

  一种由公式[I]表示的化合物：[其中R1和R2相同或不同，每个代表C1-6烷基，C3-8环烷基等；R3a，R3b和R4相同或不同，每个代表氢，C1-6烷基等；X代表—N—，—CH—等；Y表示单键，C1-3烷基，等；Y2表示C1-4烷基，氧（C1-4烷基）等；Ar1表示单环芳烃环烷基，单环芳烃杂环基等；Ar2表示5-或6-成员芳烃环烷基，芳烃杂环基等]。该化合物作为黑色素浓缩激素受体拮抗剂，并可用作例如治疗肥胖症等的治疗剂。
• 2-arylcarboxamide-nitrogenous heterocycle compound
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07531668B2

  公开（公告）日：2009-05-12

  A compound represented by the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents —N—, —CH—, et al; Y1 represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.

  一种由式[I]表示的化合物：[其中R1和R2相同或不同，每个代表C1-6烷基，C3-8环烷基等；R3a，R3b和R4相同或不同，每个代表氢，C1-6烷基等；X代表—N—，—CH—等；Y1代表单键，C1-3烷基等；Y2代表C1-4烷基，氧（C1-4烷基）等；Ar1代表单环芳香碳环基，单环芳香杂环基等；Ar2代表5-或6-成员芳香碳环基，芳香杂环基等]。该化合物作为黑色素浓缩激素受体拮抗剂，可用作例如肥胖症的治疗剂等。
• 2-ARYLCARBOXAMIDE-NITROGENEOUS HETEROCYCLE COMPOUND
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1798221A1

  公开（公告）日：2007-06-20

  A compound represented bv the formula [I]: [wherein R1 and R2 are the same or different and each represents C1-6 alkyl, C3-8 cycloalkyl, et al; R3a, R3b, and R4 are the same or different and each represents hydrogen, C1-6 alkyl, et al; X represents -N-, -CH-, et al; Y1 represents a single bond, C1-3 alkylene, et al; Y2 represents C1-4 alkylene, oxy(C1-4 alkylene), et al; Ar1 represents a monocyclic aromatic carbocyclic group, monocyclic aromatic heterocyclic group, et al; and Ar2 represents a 5- or 6-membered aromatic carbocyclic group, aromatic heterocyclic group, et al]. This compound functions as a melanin-concentrating hormone receptor antagonist and is useful as, e.g., a therapeutic agent for obesity, et al.

  式 [I] 所代表的化合物： Y2 代表 C1-4 亚烷基、氧（C1-4 亚烷基）等；Ar1 代表单环芳香碳环基团、单环芳香杂环基团等；Ar2 代表 5 或 6 元芳香碳环基团、芳香杂环基团等]。该化合物具有黑色素浓缩激素受体拮抗剂的功能，可用作肥胖症等的治疗剂。
• INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER
  申请人：Treu Matthias

  公开号：US20100184747A1

  公开（公告）日：2010-07-22

  The present invention encompasses compounds of general formula (1) wherein R 1 to R 4 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.